Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein
28 juin 2023 03h30 HE
|
Philogen
Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein Siena, Italy, 28th June 2023 – Philogen S.p.A (BIT: PHIL) today announced that it has...
Philogen Announces Clinical Trial Collaboration with MSD
01 juin 2023 02h30 HE
|
Philogen
The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and...
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
30 mai 2023 01h00 HE
|
Philogen
Mumbai, India and Siena, Italy, 30th May 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or...
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
25 mai 2023 02h00 HE
|
Philogen
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich L19TNF (also known as Fibromun) is an...
Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology
28 mars 2023 02h00 HE
|
Philogen
Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology The collaboration has focused on the...
Philogen Provides Corporate Update
01 déc. 2022 02h00 HE
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows potent activity in last-line glioblastoma in combination with LomustineOncoFAP platform shows...
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries
07 nov. 2022 11h07 HE
|
Philogen
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries The study highlights the application of DNA-Encoded Chemical...
Board of Directors Approves Half-Year Financial Report as of June 30, 2022
28 sept. 2022 13h21 HE
|
Philogen
PHILOGEN S.p.A. BOARD OF DIRECTORS APPROVES HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2022 (Courtesy English Translation) Revenues from contracts with customers amounting to €18,085 thousand...
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma
25 juil. 2022 08h00 HE
|
Philogen
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma 214 patients recruited in the study, in line with...
Philogen Provides Corporate Update
23 juin 2022 03h00 HE
|
Philogen
Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy™ treatment of Stage IIIB/C melanoma, in line with...